Concepedia

Author

Konstantin Byrgazov

Medical University of ViennaORCID

Also Known As

Byrgazov Konstantin, K Byrgazov, K. Byrgazov, Konstantin Byrgazov

27

Publications

829

Citations

11

H-Index

20

Concepts

All Affiliations

Medical University of ViennaMax Perutz LabsUniversity of ViennaLudwig Boltzmann Institute for Cardiovascular ResearchSt Anna Children's Hospital
KB

About

Konstantin Byrgazov is an author at Medical University of Vienna specializing in medicine, natural sciences, and protein synthesis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

356

2

Natural Sciences

2

2

345

3

Cell Biology

2

2

64

4

Microbiology

2

2

345

5

Engineering

1

1

11

Konstantin Byrgazov

×

10

Publications

621

Citations

10

H-Index

YearCitations

Selective Translation of Leaderless mRNAs by Specialized Ribosomes Generated by MazF in Escherichia coli

Oliver Vesper, Shahar Amitai, Maria Belitsky,

Cell

2011

292

Structural basis for the interaction of protein S1 with the Escherichia coli ribosome

Konstantin Byrgazov, Irina Grishkovskaya, Stefan Arenz,

Nucleic Acids Research

2014

64

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia

Gerwin Heller, Thaïs Topakian, Corinna Altenberger,

Leukemia

2016

56

The MazF-regulon: a toolbox for the post-transcriptional stress response in<i>Escherichia coli</i>

Martina Sauert, Michael T. Wolfinger, Oliver Vesper,

Nucleic Acids Research

2016

53

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations

Karoline V. Gleixner, Yüksel Filik, Daniela Berger,

PubMed Central

2021

41

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

Karoline V. Gleixner, Mathias Schneeweiss‐Gleixner, Gregor Eisenwort,

Haematologica

2017

39

Direct Interaction of the N-Terminal Domain of Ribosomal Protein S1 with Protein S2 in Escherichia coli

Konstantin Byrgazov, Salim Manoharadas, Anna Chao Kaberdina,

PLoS ONE

2012

31

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML

Mathias Schneeweiss‐Gleixner, Konstantin Byrgazov, Gabriele Stefanzl,

EBioMedicine

2019

21

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors

Konstantin Byrgazov, Renate Kastner, Maria W. Górna,

Leukemia

2015

13

Transposon-mediated generation of <i>BCR-ABL1</i>-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors

Konstantin Byrgazov, Chantal Lucini, Bettina Berkowitsch,

Oncotarget

2016

11

Page 1